PubMed

Incretin-based therapies: viewpoints on the way to consensus.

Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S.

Diabetes Care. 2009 Nov;32 Suppl 2:S223-31. No abstract available. PMID: 19875556 [PubMed - in process]Related articles

The effects of glucagon-like peptide-1 on the beta cell.

Vilsbøll T.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:11-8.PMID: 19878257 [PubMed - in process]Related articles

Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus.

Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsbøll T.

J Clin Endocrinol Metab. 2009 Dec;94(12):4679-87. Epub 2009 Oct 16.PMID: 19837930 [PubMed - in process]Related articles

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.

Vilsbøll T, Holst JJ, Knop FK.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):453-62.PMID: 19748063 [PubMed - in process]Related articles

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

Christensen M, Knop FK, Holst JJ, Vilsboll T.

IDrugs. 2009 Aug;12(8):503-13. Review.PMID: 19629885 [PubMed - indexed for MEDLINE]Related articles

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.

Hansen KB, Knop FK, Holst JJ, Vilsbøll T.

Int J Clin Pract. 2009 Aug;63(8):1154-60.PMID: 19624785 [PubMed - in process]Related articles

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

Giugliano D, Standl E, Vilsbøll T, Betteridge J, Bonadonna R, Campbell IW, Schernthaner GH, Staels B, Trichopoulou A, Farinaro E.

Acta Diabetol. 2009 Sep;46(3):173-81. Epub 2009 Jun 20. Review.PMID: 19543848 [PubMed - indexed for MEDLINE]Related articles

Liraglutide: a new treatment for type 2 diabetes.

Vilsboll T.

Drugs Today (Barc). 2009 Feb;45(2):101-13. Review.PMID: 19343230 [PubMed - indexed for MEDLINE]Related articles

The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.

Pilgaard K, Jensen CB, Schou JH, Lyssenko V, Wegner L, Brøns C, Vilsbøll T, Hansen T, Madsbad S, Holst JJ, Vølund A, Poulsen P, Groop L, Pedersen O, Vaag AA.

Diabetologia. 2009 Jul;52(7):1298-307. Epub 2009 Mar 14.PMID: 19288077 [PubMed - indexed for MEDLINE]Related articles

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.PMID: 19275672 [PubMed - indexed for MEDLINE]Related articles

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.

Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S.

Diabet Med. 2008 Sep;25(9):1129-31. No abstract available. PMID: 19183322 [PubMed - indexed for MEDLINE]Related articlesFree article

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T.

J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. Epub 2008 Dec 2.PMID: 19050053 [PubMed - indexed for MEDLINE]Related articles

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75.PMID: 19046215 [PubMed - indexed for MEDLINE]Related articles

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S.

Diabetologia. 2009 Feb;52(2):199-207. Epub 2008 Nov 27.PMID: 19037628 [PubMed - indexed for MEDLINE]Related articles

The incretin system and its role in type 2 diabetes mellitus.

Holst JJ, Vilsbøll T, Deacon CF.

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. Epub 2008 Aug 20. Review.PMID: 18786605 [PubMed - indexed for MEDLINE]Related articles

Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.

Vilsbøll T, Knop FK.

BioDrugs. 2008;22(4):251-7. Review.PMID: 18611067 [PubMed - indexed for MEDLINE]Related articles

Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.

Knop FK, Holst JJ, Vilsbøll T.

IDrugs. 2008 Jul;11(7):497-501. Review.PMID: 18600596 [PubMed - indexed for MEDLINE]Related articles

Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.

Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S.

Diabetes Obes Metab. 2008 Jul;10(7):593-6. Epub 2008 Apr 22. No abstract available. PMID: 18435773 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide-1, glucose homeostasis and diabetes.

Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S.

Trends Mol Med. 2008 Apr;14(4):161-8. Epub 2008 Mar 18. Review.PMID: 18353723 [PubMed - indexed for MEDLINE]Related articles

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabetologia. 2008 Apr;51(4):632-40. Epub 2008 Feb 22.PMID: 18292985 [PubMed - indexed for MEDLINE]Related articles

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S.

Diabet Med. 2008 Feb;25(2):152-6. Epub 2008 Jan 14.PMID: 18201212 [PubMed - indexed for MEDLINE]Related articles

The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T.

Regul Pept. 2007 Dec 4;144(1-3):123-30. Epub 2007 Jul 13.PMID: 17692937 [PubMed - indexed for MEDLINE]Related articles

[Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus]

Vilsbøll T, Knop FK.

Ugeskr Laeger. 2007 May 28;169(22):2101-5. Review. Danish. PMID: 17553392 [PubMed - indexed for MEDLINE]Related articles

[GLP-1-based treatment of type 2 diabetes mellitus]

Knop FK, Vilsbøll T.

Ugeskr Laeger. 2007 May 28;169(22):2095-9. Review. Danish. PMID: 17553390 [PubMed - indexed for MEDLINE]Related articles

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T.

Diabetes. 2007 Aug;56(8):1951-9. Epub 2007 May 18.PMID: 17513701 [PubMed - indexed for MEDLINE]Related articlesFree article

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.

Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A.

Gynecol Endocrinol. 2007 Jan;23(1):58-62.PMID: 17484514 [PubMed - indexed for MEDLINE]Related articles

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S.

Diabetes Care. 2007 Jun;30(6):1608-10. Epub 2007 Mar 19. No abstract available. PMID: 17372153 [PubMed - indexed for MEDLINE]Related articlesFree article

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.

Vilsbøll T.

Expert Opin Investig Drugs. 2007 Feb;16(2):231-7. Review.PMID: 17243943 [PubMed - indexed for MEDLINE]Related articles

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T.

Diabetologia. 2007 Apr;50(4):797-805. Epub 2007 Jan 16.PMID: 17225124 [PubMed - indexed for MEDLINE]Related articles

Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.

Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T.

Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E324-30. Epub 2006 Sep 5.PMID: 16954337 [PubMed - indexed for MEDLINE]Related articlesFree article

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

Vilsbøll T, Agersø H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, Krarup T, Holst JJ.

Regul Pept. 2006 Dec 10;137(3):168-72. Epub 2006 Aug 28.PMID: 16934887 [PubMed - indexed for MEDLINE]Related articles

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsbøll T.

Eur J Endocrinol. 2006 Sep;155(3):485-93.PMID: 16914604 [PubMed - indexed for MEDLINE]Related articlesFree article

On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.

Vilsbøll T.

Dan Med Bull. 2004 Nov;51(4):364-70. No abstract available. PMID: 16009062 [PubMed - indexed for MEDLINE]Related articles

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.

Schou JH, Pilgaard K, Vilsbøll T, Jensen CB, Deacon CF, Holst JJ, Vølund A, Madsbad S, Vaag AA.

J Clin Endocrinol Metab. 2005 Aug;90(8):4912-9. Epub 2005 May 17.PMID: 15899957 [PubMed - indexed for MEDLINE]Related articlesFree article

Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes.

Ørskov C, Hjorth SA, Jensen AD, Vilsbøll T.

Regul Pept. 2004 Jul 15;119(3):151-4.PMID: 15120474 [PubMed - indexed for MEDLINE]Related articles

Incretins, insulin secretion and Type 2 diabetes mellitus.

Vilsbøll T, Holst JJ.

Diabetologia. 2004 Mar;47(3):357-66. Epub 2004 Feb 13. Review.PMID: 14968296 [PubMed - indexed for MEDLINE]Related articles

Role of gastrointestinal hormones in postprandial reduction of bone resorption.

Henriksen DB, Alexandersen P, Bjarnason NH, Vilsbøll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C.

J Bone Miner Res. 2003 Dec;18(12):2180-9.PMID: 14672353 [PubMed - indexed for MEDLINE]Related articles

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

Diabetes Care. 2003 Sep;26(9):2581-7.PMID: 12941722 [PubMed - indexed for MEDLINE]Related articlesFree article

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.

Vilsbøll T, Agersø H, Krarup T, Holst JJ.

J Clin Endocrinol Metab. 2003 Jan;88(1):220-4.PMID: 12519856 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

19th Anglo-Danish-Dutch Diabetes Group meeting.

de Koning EJ, Vilsboll T, Dela F.

Diabet Med. 2002 Mar;19(3):259. No abstract available. PMID: 11918629 [PubMed - indexed for MEDLINE]Related articles

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabet Med. 2001 Feb;18(2):144-9.PMID: 11251679 [PubMed - indexed for MEDLINE]Related articles

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ.

Diabetes. 2001 Mar;50(3):609-13.PMID: 11246881 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

[Homologous intrauterine insemination as a first choice treatment of infertility]

Helmsøe-Zinck L, Vilsbøll T, Andersen AN.

Ugeskr Laeger. 1995 Jan 9;157(2):173-5. Danish. PMID: 7831731 [PubMed - indexed for MEDLINE]Related articles

[Intrauterine insemination with donor semen. Treatment of involuntary childlessness caused by male infertility]

Vilsbøll T, Helmsøe-Zinck L, Andersen AN.

Ugeskr Laeger. 1994 Aug 22;156(34):4826-9. Danish. PMID: 7992417 [PubMed - indexed for MEDLINE]Related articles